KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBITDA Margin (2016 - 2025)

Neogenomics' EBITDA Margin history spans 16 years, with the latest figure at 7.05% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 364.0% year-over-year to 7.05%; the TTM value through Dec 2025 reached 15.93%, down 199.0%, while the annual FY2025 figure was 15.93%, 199.0% down from the prior year.
  • EBITDA Margin reached 7.05% in Q4 2025 per NEO's latest filing, up from 14.38% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 7.05% in Q4 2025 to a low of 44.4% in Q1 2022.
  • Average EBITDA Margin over 5 years is 20.87%, with a median of 18.7% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -3746bps in 2021, then soared 1884bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 33.06% in 2021, then skyrocketed by 42bps to 19.02% in 2022, then soared by 37bps to 11.94% in 2023, then grew by 10bps to 10.7% in 2024, then surged by 34bps to 7.05% in 2025.
  • Per Business Quant, the three most recent readings for NEO's EBITDA Margin are 7.05% (Q4 2025), 14.38% (Q3 2025), and 26.27% (Q2 2025).